Extracorporeal shock wave lithotripsy with the Storz Modulith SL20: the first 500 patients.
Our initial experience of extracorporeal shock wave lithotripsy (ESWL) with the Storz Modulith SL20 is reported. A total of 500 patients with 551 renal and 120 ureteric stones, mean diameter 11.9 mm, underwent 746 treatments; 68.2% of patients required a single treatment. The mean treatment rate for renal calculi was 1.4 and for ureteric calculi it was 1.5, rising to 4.2 for staghorns; 62.2% of treatments were performed on an out-patient basis. Analgesia (intravenous fentanyl) was required in 60.9% of treatments for renal calculi but in only 38.2% of those for ureteric calculi. The overall stone-free rate at 3 months was 77.6%, with a further 14.7% of patients having fragments less than 3 mm in diameter that required no further treatment. The stone-free rate was dependent on the site of the stone, with the majority of residual fragments lying in a lower pole calix. There were few complications. The Modulith is an efficient and safe lithotripter capable of treating stones in the kidney and throughout the ureter.
Liston
T G
TG
Stone Centre, St Thomas' Hospital, London.
Montgomery
B S
BS
Bultitude
M I
MI
Tiptaft
R C
RC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000698:Analgesia; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008096:Lithotripsy / Q000009:adverse effects / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014545:Urinary Calculi / Q000628:therapy*
D005283:Fentanyl